Monitoring the treatment with medical cannabis in patients with chronic pain due to severe osteoarthritis through the analysis of THC, CBD, and metabolites in hair

Giuseppe Basile; Livio Tronconi; Michela  Basile; Vittorio Bolcato

doi:10.23750/abm.v95i5.16136

Monitoring the treatment with medical cannabis in patients with chronic pain due to severe osteoarthritis through the analysis of THC, CBD, and metabolites in hair

Authors

Giuseppe Basile Trauma Unit and Emergency Department, IRCCS Galeazzi Orthopedics Institute
Livio Tronconi Università Europea di Roma, Dipartimento di Scienze Umane
Michela Basile University of Messina, Department of Biomedical and Dental Sciences and Morpho Functional Imaging, Messina
Vittorio Bolcato Astolfi Associati, Law Firm, Milano https://orcid.org/0000-0002-3419-3002

DOI: https://doi.org/10.23750/abm.v95i5.16136

Keywords:

medical cannabis, drug monitoring, hair analysis , osteoarthritis

Abstract

Cannabis-based pharmaceutical preparations, or medical cannabis, are an emerging and valid option for the treatment of drug-resistant chronic pain associated with severe osteoarthritis. This article reviews the clinical implications and future developments in the therapeutic management of patients with resistant chronic pain due to severe osteoarthritis treated with medical cannabis. The use of medical cannabis may better manage resistant chronic pain due to osteoarthritis compared to the side effects associated with long-term anti-inflammatory drugs or the high risk of dependence with opioids. Different combinations of tetrahydrocannabinol (THC) and cannabidiol (CBD) can be tailored to the specific needs of the patient, optimising therapeutic efficacy and minimising side effects. The hair matrix allows for easier, non-invasive and long-term monitoring, with the possibility of simultaneous and accurate quantification of THC, CBD and their major metabolites. Hair matrix drugs monitoring could improve both the efficacy and safety of treatment, reducing the risk of unwanted side effects or improper assumption. In the future, further developments could include the ability to distinguish between different varieties of cannabis preparations and to detect an even wider range of metabolites, providing an even more comprehensive picture of therapeutic cannabis use.

References

Fitzcharles MA, Baerwald C, Ablin J, et al. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials. Schmerz 2016; 30: 47–61. doi: 10.1007/s00482-015-0084-3.

Wilson G, Yang L, Su X, et al. Exploring the therapeutic potential of natural compounds modulating the endocannabinoid system in various diseases and disorders: review. Pharmacol Rep. 2023; 75: 1410–1444. doi: 10.1007/s43440-023-00544-7.

Lo Faro AF, Venanzi B, Pilli G, et al. Ultra-high-performance liquid chromatography-tandem mass spectrometry assay for quantifying THC, CBD and their metabolites in hair. Application to patients treated with medical cannabis. J Pharm Biomed Anal. 2022 Aug 5;217:114841. doi: 10.1016/j.jpba.2022.114841.

Gottardo R, Sorio D, Musile G, et al. Screening for synthetic cannabinoids in hair by using LC-QTOF MS: a new and powerful approach to study the penetration of these new psychoactive substances in the population. Med Sci Law. 2014 Jan;54(1):22-7. doi: 10.1177/0025802413477396.

Shah I, Al-Dabbagh B, Salem AE, Hamid SAA, Muhammad N, Naughton DP. A review of bioanalytical techniques for evaluation of cannabis (Marijuana, weed, Hashish) in human hair. BMC Chem. 2019 Aug 14;13(1):106. doi: 10.1186/s13065-019-0627-2.

Cuypers E, Flanagan RJ. The interpretation of hair analysis for drugs and drug metabolites. Clin Toxicol (Phila). 2018 Feb;56(2):90-100. doi: 10.1080/15563650.2017.1379603.